| Methods | D: crossover C: unclear B: double WD: 12/49 J: 1‐1‐1 DU: 1m/2x3m (no washout)/‐ | |
| Participants | N: 49/37 D: 31 migraine with, 18 without aura C: unclear F: 69% A: 22‐68 years DU: 2‐40 years S: probably neurological practice in Denmark | |
| Interventions | P: 160 mg C: Femoxetine 400 mg | |
| Outcomes | R: 11/28 vs. 4/28 (reported only for 28 patients with baseline data) F: 1st period: 3.1 (sem 0.5) vs. 4.2 (0.3); pooled: 3.4 (sem 0.3) vs. 4.1 (0.3) attacks per 30 days in last 2 months AU: not reported HI: 15.4 vs. 18.0 AEs: more side effects with propranolol (30 vs. 14) Dropouts‐AEs: 2/49 vs. 2/49 V: (+) | |
| Notes | Baseline data for 28 patients only | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.